Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
acute myeloid leukaemia
allogeneic stem cell transplantation
melphalan
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
15
02
2024
accepted:
13
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
For patients with relapsed or refractory AML, sequential conditioning prior to allogeneic stem cell transplantation (alloSCT) is an established and potentially curative treatment option. Early response to treatment during conditioning indicates chemotherapy-responsive disease and may have prognostic value. We retrospectively evaluated blast clearance on day 5 after melphalan, administered 11 days prior to alloSCT as part of a sequential conditioning in 176 patients with active AML. Overall survival (OS) was 52% (95% confidence interval [CI] 45%-60%), and relapse-free survival (RFS) was 47% (95% CI 40%-55%) at 3 years. Patients who achieved early blast clearance did not show a significant improvement in OS and RFS (OS, hazard ratio [HR] HR 0.75, p 0.19; RFS, HR 0.71, p 0.09, respectively), but had a significantly lower non-relapse mortality rate (HR 0.46, p 0.017). HLA-mismatched donor, older age, adverse genetic risk and higher comorbidity scores were associated with inferior survival outcomes. A high initial blast count was only associated with inferior prognosis in patients receiving chemotherapy-only compared to total body irradiation containing conditioning therapy. These results indicate that for patients transplanted with active AML, sensitivity to chemotherapy might be of less importance, compared to other disease- and transplant-related factors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Duval M, Klein JP, He W, Cahn J‐Y, Cairo M, Camitta BM, et al. Hematopoietic stem‐cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–3738.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K, et al. Prospective evaluation of allogeneic hematopoietic stem‐cell transplantation from matched related and matched unrelated donors in younger adults with high‐risk acute myeloid leukemia: German–Austrian trial AMLHD98A. J Clin Oncol. 2010;28(30):4642–4648.
Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32(18):1919–1926.
Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808–813.
Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long‐term survival in past and more recent studies for relapsed AML patients: the ECOG‐ACRIN experience. Am J Hematol. 2018;93(8):1074–1081.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135(6):449–452.
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced‐intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154–1161.
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756–763.
Shimoni A, Hardan I, Shem‐Tov N, Yeshurun M, Yerushalmi R, Avigdor A, et al. Allogeneic hematopoietic stem‐cell transplantation in AML and MDS using myeloablative versus reduced‐intensity conditioning: the role of dose intensity. Leukemia. 2006;20(2):322–328.
Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H‐J. Sequential regimen of chemotherapy, reduced‐intensity conditioning for allogeneic stem‐cell transplantation, and prophylactic donor lymphocyte transfusion in high‐risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675–5687.
Steckel NK, Groth C, Mikesch J‐H, Trenschel R, Ottinger H, Kordelas L, et al. High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2018;180(6):840–853.
Holtick U, Herling M, Pflug N, Chakupurakal G, Leitzke S, Wolf D, et al. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high‐risk AML. Ann Hematol. 2017;96(3):479–487.
Chemnitz JM, von Lilienfeld‐Toal M, Holtick U, Theurich S, Shimabukuro‐Vornhagen A, Krause A, et al. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high‐risk acute myeloid leukemia. Ann Hematol. 2012;91(1):47–55.
Heinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, et al. Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia ‐ a study of the acute leukemia working party of the EBMT. Leuk Lymphoma. 2021;62(2):399–409.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak‐Weissinger E, Bunjes D, et al. Long‐term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced‐intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092–1099.
Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28(17):2859–2867.
Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, et al. Conditioning with 8‐Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood. 2005;106(9):3314–3321.
Todisco E, Ciceri F, Boschini C, Giglio F, Bacigalupo A, Patriarca F, et al. Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant. 2017;52(7):955–961.
Ringdén O, Labopin M, Schmid C, Sadeghi B, Polge E, Tischer J, et al. Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the acute Leukaemia working party of EBMT. Br J Haematol. 2017;176(3):431–439.
Fraccaroli A, Prevalsek D, Fritsch S, Haebe S, Bücklein V, Schulz C, et al. Sequential HLA‐haploidentical transplantation utilizing post‐transplantation cyclophosphamide for GvHD prophylaxis in high‐risk and relapsed/refractory AML/MDS. Am J Hematol. 2018;93(12):1524–1531.
Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, et al. High‐dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol. 2005;84(11):748–754.
Kolb H‐J, Schmid C. The FLAMSA concept‐past and future. Ann Hematol. 2020;99(9):1979–1988.
Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, et al. Sequential intensified conditioning regimen Allogeneic hematopoietic stem cell transplantation in adult patients with intermediate‐ or high‐risk acute myeloid leukemia in complete remission: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(2):278–284.
Sockel K, Stölzel F, Hönl F, Baldauf H, Röllig C, Wermke M, et al. Allogeneic stem cell transplantation with sequential Melphalan‐based conditioning in AML: residual morphological blast count determines the risk of relapse. Cancer Manag Res. 2022;14:547–559.
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55(6):1114–1125.
Copelan E, Casper JT, Carter SL, van Burik J‐AH, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007;13(12):1469–1476.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–1633.
Rodríguez‐Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, et al. Augmented FLAMSA‐Bu versus FluBu2 reduced‐intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplant. 2022;57(6):934–941.
Rodríguez‐Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et al. FLAMSA‐based reduced‐intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the acute leukemia. Biol Blood Marrow Transplant. 2020;26(11):2165–2173.
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, et al. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the acute leukemia working Party of the European Society for blood and Marrow Transplantation. Bone Marrow Transplant. 2023;58(7):784–790.
DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. HemaSphere. 2021;5(6):e572.
Stelljes M, Middeke JM, Bug G, Wagner E‐M, Mueller LP, Christoph S, et al. In patients with relapsed/refractory AML sequential conditioning and immediate Allogeneic stem cell transplantation (allo‐HCT) results in similar overall and leukemia‐free survival compared to intensive remission induction chemotherapy followed by Allo‐HC. Blood. 2022;140(Supplement 1):9–11. https://doi.org/10.1182/blood‐2022‐159962
Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley B, Manning BS, et al. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022;139(24):3546–3557.
Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman‐Grant A, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104–108.
Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, et al. Comparison of HLA‐mismatched unrelated donor transplantation with post‐transplant cyclophosphamide versus HLA‐haploidentical transplantation in patients with active acute myeloid leukemia. Bone Marrow Transplant. 2022;57(11):1657–1663.
Sauer T, Silling G, Groth C, Rosenow F, Krug U, Görlich D, et al. Treatment strategies in patients with AML or high‐risk myelodysplastic syndrome relapsed after Allo‐SCT. Bone Marrow Transplant. 2015;50(4):485–492.
Shaforostova I, Marx J, Call S, Peter Floeth M, Esseling E, Reicherts C, et al. PB2413: salvage therapy with VENETOCLAX and a HYPOMETHYLATING agent for patients with AML relapse after ALLOGENEIC stem cell transplantation. Vol 7. HemaSphere; 2023.
Herrity E, Pereira MP, Kim DDH. Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: mechanistic diversity and therapeutic directions. Br J Haematol. 2023;203(5):722–735.
Schulz F, Jäger P, Tischer J, Fraccaroli A, Bug G, Hausmann A, et al. Smart conditioning with Venetoclax‐enhanced sequential FLAMSA + RIC in patients with high‐risk myeloid malignancies. Cancers (Basel). 2024;16(3):532.
Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert Opin Biol Ther. 2022;22(5):555–561.